Another possibility for circumventing platelet toxicity and still achieving CRC tumor killing would be to use BCL-XL inhibitors with reduced oral bioavailability, which could particularly work in the context of intestinal tumors. The gene discussed is BCL2L1; the disease is intestinal neoplasm.